BAT2606 vs Mepolizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: IL-5 · full Asthma pipeline

BAT2606

Developed by Bio-Thera Solutions

Phase 1 in Asthmamonoclonal antibody
Partial signal

NCT05576454 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Cmax (Day1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 22, 29, 43, 57, 71, 85, 99, 113); AUC0-∞ (Day1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 22, 29, 43, 57, 71, 85, 99, 113): In 207 subjects enrolled and randomized, the 90% confidence intervals of the geometric mean ratios of maximum concentration and area under the curve from time 0 to infinity were within 80.00%-125.00%. (met)

Result source: NCT05576454

Mepolizumab · Nucala

Marketed by GlaxoSmithKline

Approved in Asthmamonoclonal antibody
Weak signal

NCT01691859 · Phase 3 · completed

This was an open-label, single-arm long-term extension of the prior MEA112997 trial, enrolling 347 participants who had received at least two doses in that study. Because there was no randomization, blinding, or control group, the primary safety endpoint was descriptive rather than a comparative efficacy test, although the explicit extension design provides follow-up evidence beyond the original randomized trial. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants Who Experienced On-treatment Adverse Events (AE) and On-treatment Serious Adverse Events (SAE)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66 (met)

Result source: NCT01691508

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBAT2606Mepolizumab
Severe exacerbations, annualised rate—Not reported0.5 vs 1.3−0.9 vs placebo100 mg · wk 52 · n 149NCT03562195
5 other results
  • 0.8 vs 1.7 100 mg SC · wk 32 · n 194 · Phase 3 · primary NCT01691521
  • 0.9 vs 1.7 75 mg IV · wk 32 · n 191 · Phase 3 · primary NCT01691521
  • 1.2 vs 2.4 75 mg IV · wk 52 · n 153 · Phase 2 · primary NCT01000506
  • 1.1 vs 2.4 750 mg IV · wk 52 · n 156 · Phase 2 · primary NCT01000506
  • 1.5 vs 2.4 250 mg IV · wk 52 · n 152 · Phase 2 · primary NCT01000506
Trough FEV1, change—Not reported—Not reported
ACQ-5, change—Not reported-0.8 vs -0.4−0.4 vs placebo100 mg · wk 24 · n 266NCT02281318
OCS dose reduction—Not reported-50% vs 0%−50 vs placebo100 mg SC · wk 24 · n 69NCT01691508
1 other result

Severe exacerbations, annualised rate

BAT2606
—Not reported
Mepolizumab
0.5 vs 1.3−0.9 vs placebo100 mg · wk 52 · n 149NCT03562195
5 other results
  • 0.8 vs 1.7 100 mg SC · wk 32 · n 194 · Phase 3 · primary NCT01691521
  • 0.9 vs 1.7 75 mg IV · wk 32 · n 191 · Phase 3 · primary NCT01691521
  • 1.2 vs 2.4 75 mg IV · wk 52 · n 153 · Phase 2 · primary NCT01000506
  • 1.1 vs 2.4 750 mg IV · wk 52 · n 156 · Phase 2 · primary NCT01000506
  • 1.5 vs 2.4 250 mg IV · wk 52 · n 152 · Phase 2 · primary NCT01000506

Trough FEV1, change

BAT2606
—Not reported
Mepolizumab
—Not reported

ACQ-5, change

BAT2606
—Not reported
Mepolizumab
-0.8 vs -0.4−0.4 vs placebo100 mg · wk 24 · n 266NCT02281318

OCS dose reduction

BAT2606
—Not reported
Mepolizumab
-50% vs 0%−50 vs placebo100 mg SC · wk 24 · n 69NCT01691508
1 other result
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

BAT2606
In 207 subjects enrolled and randomized, the 90% confidence intervals of the geometric mean ratios of maximum concentration and area under the curve from time 0 to infinity were within 80.00%-125.00%. NCT05576454 · Phase 1 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. BAT2606: 0 of 4 rows · Mepolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricMepolizumab
Dropout rate
n/a: no completion milestone100 mga
NCT01691859 · Phase 3 · monotherapy
show 37 more results
—Mepolizumab
NCT01691859 · Phase 3 · monotherapy
15.7%75 mg IV
NCT01000506 · Phase 2
14.7%750 mg IV
NCT01000506 · Phase 2
13.8%250 mg IV
NCT01000506 · Phase 2
—100 mg SC
NCT01691508 · Phase 3
2.1%100 mg
NCT04823585 · Phase 4 · registry result, not featured evidence
0%
NCT04765722 · Phase 4 · registry result, not featured evidence
10%100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence
4.8%100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
2.7%100 mg
NCT03562195 · Phase 3 · registry result, not featured evidence
3.6%100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
1.3%
NCT03099096 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone100 mg SC
NCT02135692 · Phase 3 · registry result, not featured evidence
0%Liquid Autoinjector
NCT03014674 · Phase 3 · registry result, not featured evidence
0%Liquid Safety Syringe
NCT03014674 · Phase 3 · registry result, not featured evidence
1.2%Lyophilized Vial
NCT03014674 · Phase 3 · registry result, not featured evidence
1.8%
NCT03021304 · Phase 3 · registry result, not featured evidence
1.8%100 mg
NCT02281318 · Phase 3 · registry result, not featured evidence
—100 mg SC
NCT02281318 · Phase 3 · registry result, not featured evidence
10.1%100 mg SC
NCT01842607 · Phase 3 · registry result, not featured evidence
4.6%100 mg SC
NCT01691521 · Phase 3 · registry result, not featured evidence
8.4%75 mg IV
NCT01691521 · Phase 3 · registry result, not featured evidence
13.7%
NCT03292588 · Phase 2 · registry result, not featured evidence
0%100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—40/100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
15.4%40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
0%75 mg IV
NCT01366521 · Phase 2 · registry result, not featured evidence
8.7%250 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
6.7%125 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
4.8%12.5 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
73.7%
NCT00802438 · Phase na · registry result, not featured evidence
Discontinued due to AEs
5.5%100 mga
NCT01691859 · Phase 3 · monotherapy
show 37 more results
—Mepolizumab
NCT01691859 · Phase 3 · monotherapy
3.3%75 mg IV
NCT01000506 · Phase 2
5.8%750 mg IV
NCT01000506 · Phase 2
5.3%250 mg IV
NCT01000506 · Phase 2
—100 mg SC
NCT01691508 · Phase 3
—100 mg
NCT04823585 · Phase 4 · registry result, not featured evidence
—
NCT04765722 · Phase 4 · registry result, not featured evidence
1%100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence
—100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT03562195 · Phase 3 · registry result, not featured evidence
0.3%100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
0.6%
NCT03099096 · Phase 3 · registry result, not featured evidence
0.9%100 mg SC
NCT02135692 · Phase 3 · registry result, not featured evidence
—Liquid Autoinjector
NCT03014674 · Phase 3 · registry result, not featured evidence
—Liquid Safety Syringe
NCT03014674 · Phase 3 · registry result, not featured evidence
—Lyophilized Vial
NCT03014674 · Phase 3 · registry result, not featured evidence
—
NCT03021304 · Phase 3 · registry result, not featured evidence
0.7%100 mg
NCT02281318 · Phase 3 · registry result, not featured evidence
—100 mg SC
NCT02281318 · Phase 3 · registry result, not featured evidence
1.7%100 mg SC
NCT01842607 · Phase 3 · registry result, not featured evidence
0.5%100 mg SC
NCT01691521 · Phase 3 · registry result, not featured evidence
0%75 mg IV
NCT01691521 · Phase 3 · registry result, not featured evidence
—
NCT03292588 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—40/100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
0%75 mg IV
NCT01366521 · Phase 2 · registry result, not featured evidence
0%250 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
0%125 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
4.8%12.5 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
—
NCT00802438 · Phase na · registry result, not featured evidence
Serious AEs
—100 mga
NCT01691859 · Phase 3 · monotherapy
show 37 more results
22.8%Mepolizumab
NCT01691859 · Phase 3 · monotherapy
13.1%75 mg IV
NCT01000506 · Phase 2
12.2%750 mg IV
NCT01000506 · Phase 2
15.8%250 mg IV
NCT01000506 · Phase 2
1.4%100 mg SC
NCT01691508 · Phase 3
4.3%100 mg
NCT04823585 · Phase 4 · registry result, not featured evidence
0%
NCT04765722 · Phase 4 · registry result, not featured evidence
3%100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence
11%100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
12.1%100 mg
NCT03562195 · Phase 3 · registry result, not featured evidence
2.3%100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
6.3%100mg
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
8.9%100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
11.9%100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
2.5%
NCT03099096 · Phase 3 · registry result, not featured evidence
24.8%100 mg SC
NCT02135692 · Phase 3 · registry result, not featured evidence
0%Liquid Autoinjector
NCT03014674 · Phase 3 · registry result, not featured evidence
0%Liquid Safety Syringe
NCT03014674 · Phase 3 · registry result, not featured evidence
0%Lyophilized Vial
NCT03014674 · Phase 3 · registry result, not featured evidence
5.4%
NCT03021304 · Phase 3 · registry result, not featured evidence
—100 mg
NCT02281318 · Phase 3 · registry result, not featured evidence
5.5%100 mg SC
NCT02281318 · Phase 3 · registry result, not featured evidence
14.4%100 mg SC
NCT01842607 · Phase 3 · registry result, not featured evidence
8.2%100 mg SC
NCT01691521 · Phase 3 · registry result, not featured evidence
7.3%75 mg IV
NCT01691521 · Phase 3 · registry result, not featured evidence
2.7%
NCT03292588 · Phase 2 · registry result, not featured evidence
10%100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
20%100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
25%40/100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
19.2%40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
25%40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
0%75 mg IV
NCT01366521 · Phase 2 · registry result, not featured evidence
0%250 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
0%125 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
4.8%12.5 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
0%
NCT00802438 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
viral upper respiratory tract infection 48.7%
headache 28.5%
upper respiratory tract infection 23.3%
NCT01691859 · Phase 3 · monotherapy
show 34 more results
75 mg IV
nasopharyngitis 22.2% (placebo 15.5%)
headache 20.9% (placebo 17.4%)
bronchitis 10.5% (placebo 9.7%)
NCT01000506 · Phase 2
750 mg IV
headache 20.5% (placebo 17.4%)
nasopharyngitis 18.6% (placebo 15.5%)
infusion related reaction 12.2% (placebo 6.5%)
NCT01000506 · Phase 2
250 mg IV
nasopharyngitis 21.7% (placebo 15.5%)
headache 21.1% (placebo 17.4%)
upper respiratory tract infection 11.2% (placebo 9.7%)
NCT01000506 · Phase 2
100 mg SC
headache 20.3% (placebo 21.2%)
nasopharyngitis 14.5% (placebo 15.2%)
bronchitis 10.1% (placebo 9.1%)
NCT01691508 · Phase 3
100 mg
musculoskeletal 4.3% (placebo 0%)
nausea, headache, dizzines 2.1% (placebo 8.3%)
skin-related symptom 2.1% (placebo 4.2%)
NCT04823585 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 26.7% (placebo 40%)
NCT04765722 · Phase 4 · registry result, not featured evidence
100 mg SC
pyrexia 5%
headache 3%
oropharyngeal pain 3%
NCT04276233 · Phase 4 · registry result, not featured evidence
100 mg SC
headache 28.3%
viral upper respiratory tract infection 16.6%
bronchitis 13.1%
NCT02654145 · Phase 4 · registry result, not featured evidence
100 mg
upper respiratory tract infection 40.9% (placebo 41.7%)
asthma 30.2% (placebo 54.3%)
nasopharyngitis 16.8% (placebo 17.9%)
NCT03562195 · Phase 3 · registry result, not featured evidence
100mg SC
nasopharyngitis 4.6% (placebo 17.2%)
abdominal pain 0% (placebo 0%)
arthralgia 0% (placebo 2%)
NCT02555371 · Phase 3 · registry result, not featured evidence
100mg
nasopharyngitis 18.8% (placebo 17.2%)
bronchitis 9.7% (placebo 3.3%)
sinusitis 9% (placebo 6%)
NCT02555371 · Phase 3 · registry result, not featured evidence
100mg SC
nasopharyngitis 20% (placebo 17.2%)
bronchitis 17.8% (placebo 3.3%)
sinusitis 11.1% (placebo 6%)
NCT02555371 · Phase 3 · registry result, not featured evidence
100mg SC
nasopharyngitis 19% (placebo 17.2%)
asthma 8.3% (placebo 9.3%)
bronchitis 8.3% (placebo 3.3%)
NCT02555371 · Phase 3 · registry result, not featured evidence
nasopharyngitis 5.7%
headache 5%
upper respiratory tract infection 3.8%
NCT03099096 · Phase 3 · registry result, not featured evidence
100 mg SC
nasopharyngitis 42.2%
bronchitis 18.9%
upper respiratory tract infection 18.9%
NCT02135692 · Phase 3 · registry result, not featured evidence
headache 11.4%
viral upper respiratory tract infection 3.8%
fatigue 2.5%
NCT03014674 · Phase 3 · registry result, not featured evidence
headache 10%
viral upper respiratory tract infection 7.5%
fatigue 1.3%
NCT03014674 · Phase 3 · registry result, not featured evidence
headache 7.1%
fatigue 5.9%
viral upper respiratory tract infection 2.4%
NCT03014674 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 7.1%
NCT03021304 · Phase 3 · registry result, not featured evidence
100 mg SC
headache 16.5% (placebo 21.2%)
nasopharyngitis 11.4% (placebo 16.5%)
upper respiratory tract infection 6.2% (placebo 5%)
NCT02281318 · Phase 3 · registry result, not featured evidence
100 mg SC
nasopharyngitis 30.1%
upper respiratory tract infection 15.2%
headache 13.4%
NCT01842607 · Phase 3 · registry result, not featured evidence
100 mg SC
headache 20.1% (placebo 17.3%)
nasopharyngitis 17% (placebo 24.1%)
upper respiratory tract infection 12.4% (placebo 14.1%)
NCT01691521 · Phase 3 · registry result, not featured evidence
75 mg IV
headache 24.1% (placebo 17.3%)
nasopharyngitis 23.6% (placebo 24.1%)
upper respiratory tract infection 11.5% (placebo 14.1%)
NCT01691521 · Phase 3 · registry result, not featured evidence
headache 10.3% (placebo 4.9%)
injection site reaction 8.9% (placebo 0%)
vomiting 8.9% (placebo 8.3%)
NCT03292588 · Phase 2 · registry result, not featured evidence
100 mg SC
headache 20%
acne 10%
alanine aminotransferase increased 10%
NCT02377427 · Phase 2 · registry result, not featured evidence
100 mg SC
bronchitis 30%
headache 30%
cough 20%
NCT02377427 · Phase 2 · registry result, not featured evidence
40/100 mg SC
nasopharyngitis 50%
abdominal pain 25%
adrenal suppression 25%
NCT02377427 · Phase 2 · registry result, not featured evidence
40 mg SC
injection site reaction 19.2%
headache 11.5%
nasopharyngitis 11.5%
NCT02377427 · Phase 2 · registry result, not featured evidence
40 mg SC
bronchitis 31.3%
headache 25%
influenza 18.8%
NCT02377427 · Phase 2 · registry result, not featured evidence
75 mg IV
arthralgia 18.2%
asthma 9.1%
back pain 9.1%
NCT01366521 · Phase 2 · registry result, not featured evidence
250 mg SC
headache 8.7%
nasopharyngitis 8.7%
abdominal distension 4.3%
NCT01366521 · Phase 2 · registry result, not featured evidence
125 mg SC
injection site reaction 20%
asthma 6.7%
dermatitis atopic 6.7%
NCT01366521 · Phase 2 · registry result, not featured evidence
12.5 mg SC
asthma 19%
injection site reaction 14.3%
nasopharyngitis 14.3%
NCT01366521 · Phase 2 · registry result, not featured evidence
upper respiratory infection 10.5%
back pain 2.6%
erythema 2.6%
NCT00802438 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Mepolizumab

Severe Exacerbation Rate Annualized 0.68 per year100 mg
event rate · per year
Extension (open-label)
No placebo or comparator arm
NCT01691859 · Phase 3 · monotherapy
ACQ -0.47 score @ 12wk100 mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01691859 · Phase 3 · monotherapy
show 17 more results
-0.55 score @ 24wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.56 score @ 36wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.55 score @ 48wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.58 score @ 60wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.51 score @ 72wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.54 score @ 84wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.44 score @ 96wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.51 score @ 112wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.66 score @ 124wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.58 score @ 136wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.54 score @ 148wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.59 score @ 164wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.49 score @ 176wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.4 score @ 188wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.45 score @ 200wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.42 score @ 216wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.47 score @ 228wk100 mg
NCT01691859 · Phase 3 · monotherapy
ACQ -0.53 score100 mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
Follow-up, n=301
NCT01691859 · Phase 3 · monotherapy
FEV1 0.124 L @ 12wk100 mg
absolute change · L
Extension (open-label)
No placebo or comparator arm
NCT01691859 · Phase 3 · monotherapy · converted to L from 124 mL as posted
show 9 more results
0.144 L @ 24wk*100 mg
NCT01691859 · Phase 3 · monotherapy · converted to L from 144 mL as posted
0.098 L @ 48wk*100 mg
NCT01691859 · Phase 3 · monotherapy · converted to L from 98 mL as posted
0.091 L @ 72wk*100 mg
NCT01691859 · Phase 3 · monotherapy · converted to L from 91 mL as posted
0.051 L @ 96wk*100 mg
NCT01691859 · Phase 3 · monotherapy · converted to L from 51 mL as posted
0.085 L @ 124wk*100 mg
NCT01691859 · Phase 3 · monotherapy · converted to L from 85 mL as posted
0.017 L @ 148wk*100 mg
NCT01691859 · Phase 3 · monotherapy · converted to L from 17 mL as posted
0.045 L @ 176wk*100 mg
NCT01691859 · Phase 3 · monotherapy · converted to L from 45 mL as posted
0.008 L @ 200wk*100 mg
NCT01691859 · Phase 3 · monotherapy · converted to L from 8 mL as posted
-0.023 L @ 228wk*100 mg
NCT01691859 · Phase 3 · monotherapy · converted to L from -23 mL as posted
Severe Exacerbation Rate Annualized 0.45 vs 1.31 placebo per year @ 52wk100 mg
event rate · per year
NCT03562195 · Phase 3 · registry result, not featured evidence
show 5 more results
0.83 vs 1.74 placebo per year @ 32wk100 mg SC
NCT01691521 · Phase 3 · registry result, not featured evidence
1.24 vs 2.4 placebo per year @ 52wk75 mg IV
NCT01000506 · Phase 2
0.93 vs 1.74 placebo per year @ 32wk75 mg IV
NCT01691521 · Phase 3 · registry result, not featured evidence
1.15 vs 2.4 placebo per year @ 52wk750 mg IV
NCT01000506 · Phase 2
1.46 vs 2.4 placebo per year @ 52wk250 mg IV
NCT01000506 · Phase 2
Time to First Moderate or Severe Exacerbation 22.8% (n=153) vs 45.2% (n=155) placebo @ 16wk75 mg IV
responder rate · % of participants
NCT01000506 · Phase 2
show 8 more results
38.2% (n=153) vs 60.4% (n=155) placebo @ 32wk75 mg IV
NCT01000506 · Phase 2
48.5% (n=153) vs 69.7% (n=155) placebo @ 52wk75 mg IV
NCT01000506 · Phase 2
18.9% (n=156) vs 45.2% (n=155) placebo @ 16wk750 mg IV
NCT01000506 · Phase 2
39.9% (n=156) vs 60.4% (n=155) placebo @ 32wk750 mg IV
NCT01000506 · Phase 2
50.1% (n=156) vs 69.7% (n=155) placebo @ 52wk750 mg IV
NCT01000506 · Phase 2
26.8% (n=152) vs 45.2% (n=155) placebo @ 16wk250 mg IV
NCT01000506 · Phase 2
45.5% (n=152) vs 60.4% (n=155) placebo @ 32wk250 mg IV
NCT01000506 · Phase 2
58.3% (n=152) vs 69.7% (n=155) placebo @ 52wk250 mg IV
NCT01000506 · Phase 2
Exacerbation Hospitalization ED Rate Annualized 0.08 vs 0.2 placebo per year @ 32wk100 mg SC
event rate · per year
NCT01691521 · Phase 3 · registry result, not featured evidence
show 4 more results
0.17 vs 0.43 placebo per year @ 52wk75 mg IV
NCT01000506 · Phase 2
0.14 vs 0.2 placebo per year @ 32wk75 mg IV
NCT01691521 · Phase 3 · registry result, not featured evidence
0.22 vs 0.43 placebo per year @ 52wk750 mg IV
NCT01000506 · Phase 2
0.25 vs 0.43 placebo per year @ 52wk250 mg IV
NCT01000506 · Phase 2
Time to First Exacerbation Leading to Hospitalization 3.4% (n=153) vs 8.6% (n=155) placebo @ 16wk75 mg IV
absolute value · percentage points
NCT01000506 · Phase 2
show 8 more results
8.3% (n=153) vs 14.8% (n=155) placebo @ 32wk75 mg IV
NCT01000506 · Phase 2
10.4% (n=153) vs 18.5% (n=155) placebo @ 52wk75 mg IV
NCT01000506 · Phase 2
3.9% (n=156) vs 8.6% (n=155) placebo @ 16wk750 mg IV
NCT01000506 · Phase 2
8% (n=156) vs 14.8% (n=155) placebo @ 32wk750 mg IV
NCT01000506 · Phase 2
12.4% (n=156) vs 18.5% (n=155) placebo @ 52wk750 mg IV
NCT01000506 · Phase 2
6.7% (n=152) vs 8.6% (n=155) placebo @ 16wk250 mg IV
NCT01000506 · Phase 2
15.1% (n=152) vs 14.8% (n=155) placebo @ 32wk250 mg IV
NCT01000506 · Phase 2
15.9% (n=152) vs 18.5% (n=155) placebo @ 52wk250 mg IV
NCT01000506 · Phase 2
Asthma Exacerbation 1.34 vs 2.46 placebo per year @ 52wk75 mg IV
absolute value · per year
NCT01000506 · Phase 2
show 2 more results
1.2 vs 2.46 placebo per year @ 52wk750 mg IV
NCT01000506 · Phase 2
1.49 vs 2.46 placebo per year @ 52wk250 mg IV
NCT01000506 · Phase 2
Time to First Exacerbation 26.1% (n=153) vs 45.9% (n=155) placebo @ 16wk75 mg IV
absolute value · percentage points
NCT01000506 · Phase 2
show 8 more results
41.5% (n=153) vs 60.9% (n=155) placebo @ 32wk75 mg IV
NCT01000506 · Phase 2
52.2% (n=153) vs 70.1% (n=155) placebo @ 52wk75 mg IV
NCT01000506 · Phase 2
19.6% (n=156) vs 45.9% (n=155) placebo @ 16wk750 mg IV
NCT01000506 · Phase 2
40.5% (n=156) vs 60.9% (n=155) placebo @ 32wk750 mg IV
NCT01000506 · Phase 2
50.8% (n=156) vs 70.1% (n=155) placebo @ 52wk750 mg IV
NCT01000506 · Phase 2
27.5% (n=152) vs 45.9% (n=155) placebo @ 16wk250 mg IV
NCT01000506 · Phase 2
45.5% (n=152) vs 60.9% (n=155) placebo @ 32wk250 mg IV
NCT01000506 · Phase 2
58.3% (n=152) vs 70.1% (n=155) placebo @ 52wk250 mg IV
NCT01000506 · Phase 2
FEV1 0.263 vs 0.126 placebo L @ 52wk100 mg
absolute change · L
NCT03562195 · Phase 3 · registry result, not featured evidence · converted to L from 262.79 mL as posted
show 51 more results
0.176 vs 0.056 placebo L @ 24wk*100 mg
NCT02281318 · Phase 3 · registry result, not featured evidence · converted to L from 176 mL as posted
0.183 vs 0.086 placebo L @ 32wk*100 mg SC
NCT01691521 · Phase 3 · registry result, not featured evidence · converted to L from 183 mL as posted
0.163 vs 0.149 placebo L @ 4wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 163 mL as posted
0.165 vs 0.154 placebo L @ 8wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 165 mL as posted
0.129 vs 0.118 placebo L @ 12wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 129 mL as posted
0.137 vs 0.135 placebo L @ 16wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 137 mL as posted
0.155 vs 0.131 placebo L @ 20wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 155 mL as posted
0.153 vs 0.148 placebo L @ 24wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 153 mL as posted
0.176 vs 0.125 placebo L @ 28wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 176 mL as posted
0.142 vs 0.139 placebo L @ 32wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 142 mL as posted
0.138 vs 0.088 placebo L @ 36wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 138 mL as posted
0.18 vs 0.125 placebo L @ 40wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 180 mL as posted
0.153 vs 0.125 placebo L @ 44wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 153 mL as posted
0.14 vs 0.091 placebo L @ 48wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 140 mL as posted
0.121 vs 0.06 placebo L @ 52wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 121 mL as posted
0.077 vs 0.059 placebo L @ 16wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 77 mL as posted
0.049 vs 0.04 placebo L @ 32wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 49 mL as posted
0.036 vs -0.009 placebo L @ 52wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 36 mL as posted
0.186 vs 0.086 placebo L @ 32wk*75 mg IV
NCT01691521 · Phase 3 · registry result, not featured evidence · converted to L from 186 mL as posted
0.112 vs 0.149 placebo L @ 4wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 112 mL as posted
0.142 vs 0.154 placebo L @ 8wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 142 mL as posted
0.136 vs 0.118 placebo L @ 12wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 136 mL as posted
0.094 vs 0.135 placebo L @ 16wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 94 mL as posted
0.124 vs 0.131 placebo L @ 20wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 124 mL as posted
0.123 vs 0.148 placebo L @ 24wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 123 mL as posted
0.095 vs 0.125 placebo L @ 28wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 95 mL as posted
0.043 vs 0.139 placebo L @ 32wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 43 mL as posted
0.119 vs 0.088 placebo L @ 36wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 119 mL as posted
0.087 vs 0.125 placebo L @ 40wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 87 mL as posted
0.111 vs 0.125 placebo L @ 44wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 111 mL as posted
0.112 vs 0.091 placebo L @ 48wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 112 mL as posted
0.115 vs 0.06 placebo L @ 52wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 115 mL as posted
0.087 vs 0.059 placebo L @ 16wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 87 mL as posted
0.017 vs 0.04 placebo L @ 32wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 17 mL as posted
0.069 vs -0.009 placebo L @ 52wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 69 mL as posted
0.137 vs 0.149 placebo L @ 4wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 137 mL as posted
0.133 vs 0.154 placebo L @ 8wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 133 mL as posted
0.115 vs 0.118 placebo L @ 12wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 115 mL as posted
0.097 vs 0.135 placebo L @ 16wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 97 mL as posted
0.089 vs 0.131 placebo L @ 20wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 89 mL as posted
0.148 vs 0.148 placebo L @ 24wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 148 mL as posted
0.089 vs 0.125 placebo L @ 28wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 89 mL as posted
0.134 vs 0.139 placebo L @ 32wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 134 mL as posted
0.133 vs 0.088 placebo L @ 36wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 133 mL as posted
0.14 vs 0.125 placebo L @ 40wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 140 mL as posted
0.093 vs 0.125 placebo L @ 44wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 93 mL as posted
0.123 vs 0.091 placebo L @ 48wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 123 mL as posted
0.14 vs 0.06 placebo L @ 52wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 140 mL as posted
0.05 vs 0.059 placebo L @ 16wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 50 mL as posted
0.072 vs 0.04 placebo L @ 32wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 72 mL as posted
0.08 vs -0.009 placebo L @ 52wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 80 mL as posted
ACQ -0.61 vs -0.45 placebo score @ 4wk75 mg IV
absolute change · score
NCT01000506 · Phase 2
show 38 more results
-0.73 vs -0.5 placebo score @ 8wk75 mg IV
NCT01000506 · Phase 2
-0.79 vs -0.63 placebo score @ 12wk75 mg IV
NCT01000506 · Phase 2
-0.8 vs -0.59 placebo score @ 16wk75 mg IV
NCT01000506 · Phase 2
-0.82 vs -0.59 placebo score @ 20wk75 mg IV
NCT01000506 · Phase 2
-0.85 vs -0.66 placebo score @ 24wk75 mg IV
NCT01000506 · Phase 2
-0.81 vs -0.7 placebo score @ 28wk75 mg IV
NCT01000506 · Phase 2
-0.74 vs -0.62 placebo score @ 32wk75 mg IV
NCT01000506 · Phase 2
-0.78 vs -0.6 placebo score @ 36wk75 mg IV
NCT01000506 · Phase 2
-0.76 vs -0.64 placebo score @ 40wk75 mg IV
NCT01000506 · Phase 2
-0.75 vs -0.62 placebo score @ 44wk75 mg IV
NCT01000506 · Phase 2
-0.72 vs -0.63 placebo score @ 48wk75 mg IV
NCT01000506 · Phase 2
-0.75 vs -0.59 placebo score @ 52wk75 mg IV
NCT01000506 · Phase 2
-0.56 vs -0.45 placebo score @ 4wk750 mg IV
NCT01000506 · Phase 2
-0.65 vs -0.5 placebo score @ 8wk750 mg IV
NCT01000506 · Phase 2
-0.72 vs -0.63 placebo score @ 12wk750 mg IV
NCT01000506 · Phase 2
-0.76 vs -0.59 placebo score @ 16wk750 mg IV
NCT01000506 · Phase 2
-0.72 vs -0.59 placebo score @ 20wk750 mg IV
NCT01000506 · Phase 2
-0.79 vs -0.66 placebo score @ 24wk750 mg IV
NCT01000506 · Phase 2
-0.73 vs -0.7 placebo score @ 28wk750 mg IV
NCT01000506 · Phase 2
-0.74 vs -0.62 placebo score @ 32wk750 mg IV
NCT01000506 · Phase 2
-0.76 vs -0.6 placebo score @ 36wk750 mg IV
NCT01000506 · Phase 2
-0.67 vs -0.64 placebo score @ 40wk750 mg IV
NCT01000506 · Phase 2
-0.69 vs -0.62 placebo score @ 44wk750 mg IV
NCT01000506 · Phase 2
-0.68 vs -0.63 placebo score @ 48wk750 mg IV
NCT01000506 · Phase 2
-0.8 vs -0.59 placebo score @ 52wk750 mg IV
NCT01000506 · Phase 2
-0.5 vs -0.45 placebo score @ 4wk250 mg IV
NCT01000506 · Phase 2
-0.6 vs -0.5 placebo score @ 8wk250 mg IV
NCT01000506 · Phase 2
-0.65 vs -0.63 placebo score @ 12wk250 mg IV
NCT01000506 · Phase 2
-0.52 vs -0.59 placebo score @ 16wk250 mg IV
NCT01000506 · Phase 2
-0.61 vs -0.59 placebo score @ 20wk250 mg IV
NCT01000506 · Phase 2
-0.7 vs -0.66 placebo score @ 24wk250 mg IV
NCT01000506 · Phase 2
-0.66 vs -0.7 placebo score @ 28wk250 mg IV
NCT01000506 · Phase 2
-0.76 vs -0.62 placebo score @ 32wk250 mg IV
NCT01000506 · Phase 2
-0.75 vs -0.6 placebo score @ 36wk250 mg IV
NCT01000506 · Phase 2
-0.73 vs -0.64 placebo score @ 40wk250 mg IV
NCT01000506 · Phase 2
-0.77 vs -0.62 placebo score @ 44wk250 mg IV
NCT01000506 · Phase 2
-0.74 vs -0.63 placebo score @ 48wk250 mg IV
NCT01000506 · Phase 2
-0.87 vs -0.59 placebo score @ 52wk250 mg IV
NCT01000506 · Phase 2

+ 36 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT2606's landscape · Mepolizumab's landscape